Mastering tus Basal Profile: Siab -Purity Insulin Degludec API (CAS 844439-96-9)
Aug 14, 2026
Tso lus
Kev tsim kho lub tiaj tus basal Profile: High-Fidelity Insulin Degludec API (CAS 844439-96-9)
Kev Tshawb Fawb R&D ntawm Ntau-Hexameric Assembly, Site-Specific Acylation, thiab Ultra-Long-Tswj Peptide Synthesis.
Muaj tseeb 24-teev cov hauv paus kev pab them nqi yuav tsum muaj molecule muaj peev xwm los tsim ib tug sustained, uninterrupted subcutaneous depot.Insulin Degludec (CAS 844439-96-9)sawv cev rau qhov kawg ntawm basal insulin engineering. Ua tiav ib nrab- lub neej dhau 25 teev thiab lub sijhawm ua haujlwm dhau 42 teev, nws muab qhov tsis tau pom dua los ntawm cov tshuaj pharmacokinetic profile. Txawm li cas los xij, kev tsim cov txheej txheem no, acylated peptide yuav tsum muaj qhov tshwj xeeb stereochemical precision. Crude synthesis inevitably yields structurally compromised analogues uas puas lub depot tsim. Cov ntaub ntawv thev naus laus zis no nthuav tawm cov txheej txheem kev sib dhos hexameric ntawm Degludec, nthuav tawm cov tshuaj lom neeg cov teeb meem ntawm cov saw hlau sab nraud, thiab qhia txog cov qauv kev tsim qauv kev cai lij choj ua tiav ntawm Xi'an Tihealth.
1. Molecular Architecture: Lub Physics ntawm Subcutaneous Depot
Insulin Degludec ua tiav nws qhov ultra- ntev ntev tsis yog los ntawm kev hloov pauv receptor affinity, tab sis los ntawm kev tswj hwm nws lub cev hauv cov ntaub so ntswg subcutaneous. Cov molecule yog muab los ntawm tib neeg cov tshuaj insulin nrog ob qhov kev hloov pauv ntawm cov qauv: kev tshem tawm ntawm threonine ntawm txoj hauj lwm B30, thiab covalent txuas ntawm 16-carbon fatty diacid (hexadecanedioic acid) rau lysine ntawm txoj hauj lwm B29 ntawm glutamic acid spacer.
Multi-Hexameric Assembly
Hauv cov tshuaj vial, Degludec muaj nyob ruaj khov, soluble di-hexamers nyob rau hauv muaj cov ntsiab lus tshwj xeeb ntawm zinc (Zn2+) thiab phenol. Tam sim ntawd tom qab txhaj tshuaj subcutaneous, phenol sai sai diffuses mus rau hauv cov kua dej nruab nrab ib puag ncig. Qhov kev hloov tam sim no nyob rau hauv cov tshuaj microenvironment ua rau lub cim fatty acid sab chains hla - txuas hexamers uas nyob ib sab. Cov qauv tsim tau yog qhov loj heev, ruaj khov heev, linear multi- hexamer saw uas ua raws li cov kua dej hauv zos.
Rate -Kev txwv Zinc Depletion
Lub dissociation ntawm no loj heev multi- hexamer depot dictates tus nqi nqus. Raws li zinc ions maj mam diffuse deb ntawm qhov kawg ntawm ntau - hexamer chains, cov qauv maj mam tawg mus rau hauv dimers thiab nws thiaj li pharmacologically active monomers. Qhov kev tswj hwm lub cev tsis sib haum xeeb no yog lub hauv paus txheej txheem uas lav qhov tsis tu ncua, tsis muaj qhov tso tawm ntawm insulin molecules mus rau hauv cov hlab ntsha hauv lub sijhawm ntev dua 42 teev.
Albumin Binding hauv Systemic Circulation
Qhov thib ob buffering mechanism tshwm sim thaum cov monomers nkag mus rau hauv cov hlab ntsha. Lub hexadecanedioic acid sab saw pom muaj kev sib raug zoo rau kev ncig cov ntshav albumin. Tshaj li 99% ntawm Degludec khi rau albumin thaum nkag mus rau hauv lub cev, tsim kom muaj cov khoom siv hauv nruab nrab. Qhov no dual -depot mechanism tag nrho flattens lub pharmacokinetic nkhaus, zoo tshem tawm lub siab ncov uas precipitate hypoglycemic ntu.
2. Forensic Formulation Matrix: Degludec vs. First-Generation Basals
Kev hloov pauv ntawm thawj - tiam basal insulins mus rau Degludec xav kom cov neeg tsim qauv rov xav txog cov tshuaj ib puag ncig ntawm cov khoom siv tshuaj zaum kawg. Kev nkag siab txog qhov sib txawv ntawm lub cev muaj zog yog qhov tseem ceeb rau kev yuav khoom thiab QA pab pawg tsom xam API qhov tsim nyog.
| Pharmacokinetic Parameter | Insulin Glargine (1st Gen Basal) | Xi'an Tihealth Degludec API (CAS 844439-96-9) |
|---|---|---|
| Formulation pH | Acid (pH 4.0). Tsis tuaj yeem sib xyaw nrog nruab nrab nrawm - ua haujlwm insulins. | Neutral (pH 7.4). Cov miscible heev; tso cai rau co-formulation (eg, IDegLira). |
| Depot Mechanism | Isoelectric nag lossis daus hauv cov ntaub so ntswg subcutaneous (micro-crystal formation). | Soluble multi-hexamer sib dhos dictated los ntawm phenol/zinc diffusion. |
| Ib nrab-Lub Neej (t1/2) | ~ 12 teev. Feem ntau yuav tsum nruj tib yam - sij hawm noj txhua hnub. | >25 teev. Txhawb qhov hloov pauv hloov pauv qhov rais txhua hnub yam tsis muaj kev cuam tshuam txog kev tswj hwm. |
| Hnub - mus rau - Hnub Variability | Kev hloov pauv nruab nrab raws li qhov chaw txhaj tshuaj vascularity. | Qhov qis tshaj hauv nruab nrab- tus neeg mob sib txawv coefficient ntawm tag nrho cov basal insulins. |
3. Xi'an Tihealth Advantage: Precision Peptide Acylation
Synthesizing acylated insulin analogues sawv cev rau kev sib tw loj heev hauv kev tsim tshuaj. Cov chaw soj ntsuam dav dav feem ntau ua tsis tiav ntawm theem acylation, ua rau muaj kev puas tsuaj loj ntawm di-acylated impurities, desamido-insulin degradation cov khoom, thiab siab -molecular- hnyav polymers (HMWP). Txawm tias me me steric hindrance yuam kev thaum lub sij hawm txuas ntawm gamma -glutamyl spacer cuam tshuam lub hexameric los ua ke mechanism, ua rau API kev kho mob tsis muaj txiaj ntsig.
NtawmXi'an Tihealth Biotechnology Co., Ltd., peb ua raws li kev soj ntsuam nruj me ntsis hybrid synthesis raws tu qauv tsim los lav cov qauv kev ncaj ncees:
Site -Specific LysB29 Acylation
Peb siv cov pab pawg tiv thaiv orthogonal thaum lub sijhawm sib txuas los tiv thaiv N-terminal amines. Qhov no tswj hwm qhov chaw nruj me ntsis- tshwj xeeb conjugation ntawm hexadecanedioic acid nkaus xwb ntawm LysB29 residue. Cov txheej txheem no tshem tawm tag nrho cov tsim ntawm random poly-acylated impurities uas plague substandard API batches.
Multi-Dimensional Prep-HPLC
Tshaj tawm - acylation cov tshuaj tiv thaiv sib xyaw muaj cov khoom lag luam zoo sib xws. Peb lub chaw ua haujlwm tau txais kev lag luam - nplai Preparative High-Kev Ua Haujlwm Ua Kua Dej Chromatography (Prep-HPLC) nrog kev ua kom zoo tshaj plaws gradient elution. Qhov no cais qhov tseeb Degludec macromolecule, tsav tsheb purity qib dhau losNtau dua lossis sib npaug li 99.0%thaum txo qis HMWP ntau ntau.
Kev tswj hwm nruj Endotoxin
Muab hais tias Degludec yog tsim tshwj xeeb rau kev tswj xyuas parenteral, kev kis kab mob lom yog qhov tseem ceeb tsis ua haujlwm. Peb cov txheej txheem API crystallization thiab lyophilization tshwm sim hauv ISO Class 5 cleanrooms. Cov kab mob endotoxins tau nruj me ntsis tswj hauv qab cov kev txwv pharmacopeial, ua kom tag nrho cov neeg mob muaj kev nyab xeeb thaum xa khoom subcutaneous.
4. Muaj Scenarios rau Degludec Formulations
Vim tias Insulin Degludec yog cov soluble tag nrho ntawm lub cev pH, nws hla cov txheej txheem fwj uas cuam tshuam nrog cov laus acidic insulins, qhib kev siv tshuaj kho mob siab heev:
Co-Formulation Injectables (eg, GLP-1 Combinations)
Tsis zoo li Glargine, qhov nruab nrab pH ntawm Degludec tso cai rau kev ruaj ntseg ib leeg - cwj mem co- cov qauv nrog GLP-1 receptor agonists (xws li Liraglutide lossis Semaglutide) lossis sai - ua cov insulins (xws li Aspart), tsis tsim cov tshuaj tiv thaiv kab mob sib kis.
Siab -Concentration Basal cwjmem (U-200 hom)
Vim nws cov solubility siab nyob rau hauv zinc -phenol matrices, peb API pab txhawb cov compounding ntawm concentrated U-200 formulations. Qhov no ua rau txo qis lub cev ntim ntawm kev txhaj tshuaj, ua rau cov neeg mob muaj kev nplij siab thiab ua raws li cov tib neeg xav tau cov tshuaj insulin ntau txhua hnub.
Formulator & Procurement FAQ
API yuav tsum tau muab sib xyaw ua ke rau hauv cov txheej txheem excipient matrix uas muaj zinc acetate, phenol, thiab meta-cresol ntawm pH ntawm kwv yees li 7.4. Nyob rau hauv lub vial, zinc yuam cov peptide mus rau hauv di-hexamer xeev, thaum lub phenol ua raws li ib tug steric blocker, tiv thaiv lub ntev fatty acid chains los ntawm interacting. Thaum txhaj tshuaj, cov phenol diffuses tam sim ntawd, tso cai rau cov hlua sab nraud hla -txuas cov hexamers mus rau hauv qhov chaw ua haujlwm subcutaneous.
Tsis zoo li cov khoom siv qhov ncauj APIs, complex acylated peptides raug thermal degradation sai. Tom qab lyophilization, cov hmoov qhuav tau muab ntim rau hauv aseptic aluminium foil hnab hauv qab cov roj inert. Kev thauj khoom thoob ntiaj teb yog tswj hwm tshwj xeeb los ntawm kev txias txias-chain logistics (feem ntau khaws cia ntawm 2℃txog 8℃lossis sib sib zog nqus- khov, cuam tshuam rau lub sijhawm thauj tshwj xeeb), siv qhov ntsuas kub tsis tu ncua- taug qab cov ntaub ntawv loggers kom lav qhov ruaj khov molecular thaum tuaj txog.
Yog lawm. Kev ua haujlwm raws li ISO9001: 2015 lub moj khaum nruj, Xi'an Tihealth muab cov pob kev qhia dav dav nrog txhua qhov xa tawm. Qhov no suav nrog Daim Ntawv Pov Thawj Kev Ntsuam Xyuas (COA), siab- daws teeb meem HPLC chromatograms lees paub lub hom phiaj purity thiab impurity cais, LC-MS validation, thiab nruj kab mob endotoxin cov ntaub ntawv, streamlining koj downstream R&D validation thiab tswj cov txheej txheem zoo.
Txhim kho koj cov kav dej kho mob nrog ultra- ntshiab, qhov chaw - tshwj xeeb acylated peptide APIs.
Thov HPLC Chromatogram & Bulk PricingSau los ntawm Wang Xueyan, Technical Operations & Formulation Strategy ntawm Xi'an Tihealth Biotechnology Co., Ltd.
* Kev lees paub tsis raug cai: Muab tshwj xeeb raws li qhov tsis muaj npe, kev tshawb fawb -qib Cov Khoom Siv Tshuaj (API). Cov koom haum kev yuav khoom tsuas yog lub luag haujlwm rau kev tsim kho zaum kawg, kev sim tshuaj ntsuam xyuas, kev nyab xeeb sib xyaw, thiab kev tswj hwm nruj hauv lawv txoj cai thoob ntiaj teb.*
Xa kev nug